Weight Loss Jabs: Who is Accessing Them and Why Equity Concerns are Rising

Novel research reveals a significant disparity in access to weight loss medications like Mounjaro and Wegovy in the UK, with women and individuals from more affluent backgrounds being the most likely to utilize these treatments. While the National Health Service (NHS) is initiating a phased rollout, the majority of current prescriptions are private, raising concerns about equitable access to these potentially life-changing drugs.

Disparities in Access: A Closer Look

Analysis of 113,630 private prescriptions issued between November 2024 and October 2025, conducted by The Health Foundation in collaboration with Voy, highlights several key trends:

• Gender: Approximately 80% of private prescriptions for weight loss jabs are filled by women. Source
• Age: The highest uptake is observed among individuals aged 30 to 49, with a sharp decline in prescriptions after age 60. Source
• Socioeconomic Status: Individuals in the most deprived areas are around a third less likely to receive these jabs compared to those in the least deprived areas, despite experiencing higher rates of obesity. Source
• BMI at Treatment Initiation: People in more deprived areas tend to begin treatment with a higher Body Mass Index (BMI), with around 45% of 30-49 year olds starting treatment with a BMI of 35 or above, compared to around 30% in the least deprived areas. Source

NHS Rollout and Prioritization

The NHS is currently implementing a phased rollout of Mounjaro, prioritizing individuals with a BMI over 40 and those with co-existing health conditions such as high blood pressure and type 2 diabetes. The initial phase will focus on approximately 220,000 patients over the first three years, with a full rollout expected to take 12 years. Source

An NHS spokesperson emphasized that prioritization is based on clinical need and that efforts are underway to accelerate access for eligible individuals across England. Source

The Need for Preventative Measures

Samantha Field, senior fellow in prevention at The Health Foundation, warns that with an estimated 2.4 million people in the UK already prescribed weight loss medications, the current disparities are concerning. She stresses the importance of focusing on preventative measures, such as promoting healthy eating habits, alongside ensuring equitable access to treatment. Source

Recent government initiatives, such as the ban on junk food advertisements, aim to address the root causes of obesity and promote healthier lifestyles.

Key Takeaways

• Weight loss jabs are currently more accessible to women and individuals from higher socioeconomic backgrounds.
• The NHS rollout prioritizes those with the greatest clinical need, but access remains uneven.
• Preventative measures are crucial to address the underlying causes of obesity and ensure equitable access to treatment.